Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
=== Mammoth === MAMMOTH approaches the alignment problem from a different objective than almost all other methods. Rather than trying to find an alignment that maximally superimposes the largest number of residues, it seeks the subset of the structural alignment least likely to occur by chance. To do this it marks a local motif alignment with flags to indicate which residues simultaneously satisfy more stringent criteria: 1) Local structure overlap 2) regular secondary structure 3) 3D-superposition 4) same ordering in primary sequence. It converts the statistics of the number of residues with high-confidence matches and the size of the protein to compute an Expectation value for the outcome by chance. It excels at matching remote homologs, particularly structures generated by ab initio structure prediction to structure families such as SCOP, because it emphasizes extracting a statistically reliable sub alignment and not in achieving the maximal sequence alignment or maximal 3D superposition. For every overlapping window of 7 consecutive residues it computes the set of displacement direction unit vectors between adjacent C-alpha residues. All-against-all local motifs are compared based on the URMS score. These values become the pair alignment score entries for dynamic programming which produces a seed pair-wise residue alignment.
=== GC–tandem MS === When a second phase of mass fragmentation is added, for example using a second quadrupole in a quadrupole instrument, it is called tandem MS (MS/MS). MS/MS can sometimes be used to quantitate low levels of target compounds in the presence of a high sample matrix background. The first quadrupole (Q1) is connected with a collision cell (Q2) and another quadrupole (Q3). Both quadrupoles can be used in scanning or static mode, depending on the type of MS/MS analysis being performed. Types of analysis include product ion scan, precursor ion scan, selected reaction monitoring (SRM) (sometimes referred to as multiple reaction monitoring (MRM)) and neutral loss scan. For example: When Q1 is in static mode (looking at one mass only as in SIM), and Q3 is in scanning mode, one obtains a so-called product ion spectrum (also called "daughter spectrum"). From this spectrum, one can select a prominent product ion which can be the product ion for the chosen precursor ion. The pair is called a "transition" and forms the basis for SRM. SRM is highly specific and virtually eliminates matrix background.
Migraine is a complex pain disorder involving both blood vessels and neurons within the meninges, the brain's protective layers. The system involved is sometimes referred to as the trigeminovascular system. The trigeminal nerve, located within the dura mater, carries sensory information about pain, touch, heat, and cold from the face to the brain. The hypothalamus receives input from the trigeminal nerve and can modulate its activity. Individuals with migraine appear to experience impairments in cortical habituation, a process which would normally decrease the brain's response to repetitive sensory stimuli. Migraine attacks may begin with disruption in the hypothalamus and limbic system. Gradually increasing hypothalamic activity has been observed in the period leading up to a migraine attack, followed by a disruption or collapse of hypothalamic connectivity to the limbic system during an attack. Disruption of the connection between the hypothalamus and limbic system may increase activity in the pain pathway from the trigeminal nerve to the brain, resulting in a migraine attack. The meninges, particularly the dura mater, are rich in pain-sensitive nerve endings. Sensory information travels along trigeminal nerve fibers to cell bodies located within the trigeminal ganglion. Axons of the trigeminal ganglion (TG) neurons enter the brainstem and travel to the trigeminal nucleus caudalis (TNC). The activity of calcitonin gene-related peptide (CGRP) in the meninges is linked to migraine.
Females are more aggressive than males during the courtship period, often fighting for access to mates, with fights among females accounting for more than half the aggressive interactions during this period. If females court a male that already has a partner, the incumbent female will try to repel the competitor, usually by chasing and kicking. These interactions can be prolonged, lasting up to five hours, especially when the male being fought over is single and neither female has the advantage of incumbency. In these cases, the females typically intensify their calls and displays. The sperm from a mating is stored by the female and can suffice to fertilise about six eggs. The pair mate every day or two, and every second or third day the female lays one of a clutch of five to fifteen very large, thick-shelled, green eggs. The shell is around 1 mm (0.04 in) thick, but rather thinner in northern regions according to indigenous Australians. The shell is substantially composed of calcite, and its δ13C is a function of the emu's diet. The eggs are on average 13 cm × 9 cm (5.1 in × 3.5 in) and weigh between 450 and 650 g (1.0 and 1.4 lb). The maternal investment in the egg is considerable, and the proportion of yolk to albumen, at about 50%, is greater than would be predicted for a precocial egg of this size. This probably relates to the long incubation period which means the developing chick must consume greater resources before hatching. The first verified occurrence of genetically identical avian twins was demonstrated in the emu. The egg surface is granulated and pale green.
Sources: en.wikipedia.org
=== Wet media milling (nanocrystal technology) === In wet media milling, the drug substance is suspended in an aqueous solution containing a stabilizing surfactant or polymer and circulated through a chamber filled with small (typically 0.2–0.5 mm) ceramic, glass, or polymer-coated beads. Bead-on-bead and bead-on-particle impacts progressively reduce the drug particle size to the 100–400 nm range, while the stabilizer adsorbs onto newly created surfaces and prevents agglomeration. The technology, commercialized as NanoCrystal by Elan Drug Technologies (later Alkermes), underpins several U.S. Food and Drug Administration–approved products, including sirolimus (Rapamune oral tablet, approved 2000), aprepitant (Emend, 2003), fenofibrate (Tricor 145 mg, 2004; Triglide, 2005), and megestrol acetate (Megace ES, 2005).
And although such interventions were later found to be ineffective for their intended purposes, those works led to the creation of tissue engineering, techniques for cardiopulmonary bypass and dialysis, established the foundation for the technologies for storing organs extracted from a person outside the body (which now are used, for example, during organ donation), the emergence of cryobiology. 1920s–1930s In medical practice, sex gland transplants were introduced to obtain rejuvenating effects. (Though separate experiments in this direction were done even earlier, even in antiquity.) The earlier mentioned operations of Dr. Frank Lydston in 1914 remained almost unnoticed. But the works of Leo Leonidas Stanley quickly received widespread scientific notice. Stanley was a physician at a prison in California and began to do these operations since 1919, using glands of executed criminals. In the following years, such operations were done by dozens of physicians (including Eugen Steinach) but they became most famous due to the activity of the French surgeon of Russian extraction Serge/Samuel Voronoff. It was believed that transplantation of sex glands provides more durable effects than injection of a suspension of ground glands. In case of transplantation from human to human, the glands of executed criminals were usually used. But due to a shortage of materials, the sex glands of young healthy monkeys were widely used, which were specially grown for this purpose (usually thin sections of the glands were implanted).
==== Human Resource Management ==== A practical application of positive psychology is to assist individuals and organizations in identifying strengths so as to increase and sustain well-being. Therapists, counselors, coaches, various psychological professionals, HR departments, business strategists, and others, are using new methods and techniques to broaden and build upon the strengths of a wide population of individuals. This includes those not suffering from mental illness or disorder.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.